Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

Although it was only two months ago that I identified Synpatics (SYNA) as one of my two “Top Tech Takeover Targets”, recently released insider trading activity by the company’s officers suggest they don’t have much confidence in the company’s future. Over the past six months, every one of the… Read More

What Is Trump’s Deal?

We have to be careful when drawing conclusions about a president’s affect on stock market and the economy. For example, traditionally the pro-business Republican Party is regarded as good for the stock market, while the more regulatory-minded Democratic Party is viewed as an impediment to economic growth. However, no evidence supports those… Read More

As we reported in our Alert last week, shares of Argos Therapeutics took a hit after the company announced terms of an upcoming secondary stock offering that took the market by surprise. The company is raising another $50 million with this offering, in addition to the $60 raised from… Read More

Balm for Gilead

Shares of Personal Finance Growth Portfolio holding Gilead Sciences (GILD) dropped nearly 9% in early trading on Tuesday after the company released its third quarter earnings report that fell short of last year’s results. Quarterly revenue of $7.8 billion this year was less than last year’s sales of $8.2 billion,… Read More

An update for all subscribers who still own the VF Corporation August 62.5 puts (initial sale Alert was issued last week). The stock continues to drift lower and the puts traded at $1.83 this morning, close to the $1.90 high from last week. I think this is a good exit… Read More

Argos Therapeutics (ARGS) announced yesterday evening the terms of its upcoming secondary stock offering, which has sent its share price down more than 15% this morning to partially offset the dilution that will occur after the offering has been completed. The company intends to raise $50 million compared to its… Read More

Cancer immunotherapy company ZIOPHARM Oncology (ZIOP) disclosed on July 15th that a patient in one of its brain cancer trial groups died after being treated with its experimental drug treatment, and two other patients also passed away for reasons unrelated to this form of therapy. As we noted… Read More

Old Tech Firms: The New Bonds

A trio of “old tech” companies reported quarterly earnings this week, which in the past would have drew yawns from stock market analysts. But with overseas investors fleeing the uncertainty of Europe and Asia for the relative security of the United States, many of these stocks have become de facto… Read More

When we launched Breakthrough Tech Profits two months ago, we knew our stock picks were good, but we also thought our timing was, too. We expected a flood of investor money would soon flow into technology-intensive companies that could generate bigger profits in a stagnant global economy. Still, we didn’t… Read More